IP Library Granted Patent US 9,296,803
Granted Patent B2
US 9,296,803 · App. 13/577,990 · Granted Mar 29, 2016

Methods and compositions containing Fc fusion proteins for enhancing immune responses

Inventor: Danuta Kozbor (Buffalo, NY)
Assignee: Health Research, Inc.
C07K14/521A61K39/0011A61K2039/505A61K2039/572C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,296,803
App. No.
13/577,990
Granted
Mar 29, 2016
Kind
B2
Abstract

Provided are compositions and methods for inhibiting cell growth. The cells that are targeted by the compositions and methods of the invention express an antigen, a mimotope of the antigen, or a CXCR4 chemokine receptor. The method entails administering to an individual a polynucleotide encoding an immunoglobulin Fc and an antigen expressed by the cells or a mimotope of the antigen. The method also involves administering to the individual a composition which contains a polynucleotide encoding an immunoglobulin Fc and an antagonist peptide of a CXCR4 chemokine receptor expressed by the cells. Also provided are proteins encoded by the polynucleotides.

Claims (6)

1. A method for inhibiting growth of tumor cells in an individual comprising administering to the individual a composition comprising a polynucleotide encoding a protein, wherein the protein encoded by the polynucleotide consists of:

an immunoglobulin Fc region and only one amino acid sequence of an antagonist peptide of a receptor expressed by the tumor cells, wherein the only one amino acid sequence of the antagonist peptide of the receptor consists of the sequence KGVSLSYR (SEQ ID NO:6);

such that growth of the tumor cells that express the receptor is inhibited subsequent to the administration, and wherein the polynucleotide encoding the protein is present in a recombinant oncolytic vaccinia virus.

2. The method of claim 1 , wherein the Fc is a human IgG1 Fc or human IgG3 Fc.

3. The method of claim 1 , wherein the administration is a systemic administration.

4. The method of claim 1 , wherein the immunoglobulin Fc does not comprise an antigen binding portion of an immunoglobulin.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 25, 2012
From: ROSWELL PARK CANCER INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029034/0532 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2012
From: KOZBOR, DANUTA
To: HEALTH RESEARCH, INC.
Reel/Frame 028979/0059 →
Continuity (2)
Provisional Application 61312982 · Mar 11, 2010
Related Publication 20130011436A1 · Jan 10, 2013